Effectiveness and Cost-effectiveness of Thrombolysis in Submassive Pulmonary Embolism

Daniella J. Perlroth, MD; Gillian D. Sanders, PhD; Michael K. Gould, MD, MS

Background: Thrombolytic therapy is controversial in patients with submassive pulmonary embolism.

Methods: We performed a cost-effectiveness analysis to compare health effects and costs of treatment with alteplase plus heparin sodium vs heparin alone in hemodynamically stable patients with pulmonary embolism and right ventricular dysfunction by developing a Markov model and using data from clinical trials and administrative sources.

Results: Based on data from a recent randomized trial, we assumed that the risk of clinical deterioration requiring treatment escalation was almost 3 times higher in patients who received heparin alone (23.2% vs 7.6%) but that the risk of death was equal in the 2 cohorts (2.7%). Based on registry data, we assumed that the risk of intracranial hemorrhage was approximately 3 times higher in patients who received alteplase plus heparin (1.2% vs 0.4%). Under these and other assumptions, thrombolysis resulted in marginally higher total lifetime health care costs ($43 900 vs $43 300) and was slightly less effective (10.52 vs 10.57 quality-adjusted life-years) than treatment with heparin alone. Thrombolysis was more effective and cost less than $50 000 per quality-adjusted life-year gained when we assumed that the baseline risk of death in the heparin group was 3 times the base-case value (8.1%) and that alteplase reduced the relative risk of death by at least 10%.

Conclusions: Available data do not support the routine use of thrombolysis to treat patients with submassive pulmonary embolism. However, thrombolysis may prove to be cost-effective in selected subgroups of hemodynamically stable patients in whom the risk of death is higher.
hemodynamically stable patients with acute pulmonary embolism and right ventricular dysfunction.

METHODS

We developed a Markov (state-transition) model to estimate the effectiveness and costs of treatment for acute pulmonary embolism.\textsuperscript{13} We adopted the recommendations of the panel on Cost-effectiveness in Health and Medicine\textsuperscript{16} for conducting and reporting a reference-case analysis from the societal perspective.

Figure 1 outlines the structure of the decision model; it illustrates the clinical problem, initial treatment strategy, possible requirement for treatment escalation, and patient outcomes. The target population included hemodynamically stable patients with submassive pulmonary embolism and right ventricular dysfunction. A hemodynamically stable patient was defined as one with a systolic blood pressure higher than 90 mm Hg.

We compared initial treatment with alteplase plus heparin vs treatment with heparin alone. Patients in either group who developed clinical deterioration based on worsening cardio-pulmonary signs and symptoms required treatment escalation. Treatment escalation included the need for secondary or “rescue” thrombolysis, mechanical ventilation, catecholamine infusion, or embolectomy. Other outcomes included intracranial hemorrhage, severe and minor bleeding at other sites, recurrent pulmonary embolism, long-term disability from intracranial hemorrhage, time lost from work or leisure due to pulmonary embolism or treatment complications, and death from pulmonary embolism.

We gathered data about the effectiveness and safety of treatment strategies by reviewing clinical studies from the peer-reviewed literature, which we identified by searching MEDLINE and EMBASE from 1966 to December 2003. We updated the search in February 2006. We also scanned the reference lists of original research and review articles. We limited the search to English-language publications.

Base-case estimates for clinical probabilities, costs, and health state utilities (quality-of-life adjustments) are listed in Table 1 and Table 2. We derived estimates of effectiveness from the largest randomized, controlled trial of thrombolysis in patients with submassive pulmonary embolism.\textsuperscript{14} Estimates of the risk of bleeding complications were derived from other clinical data sources.\textsuperscript{13,17-19} We estimated direct costs associated with pulmonary embolism treatment by adding costs for hospital care, physician services, and pharmaceuticals. We discounted all costs and health effects at an annual rate of 3%. We estimated resource utilization by using data from clinical trials and valued resources by using Medicare reimbursement rates and other administrative data sources. Details about additional assumptions and data sources are available at http://pulmonary.stanford.edu/documents/thrombolysis_appendixonly.pdf.

We expressed our results in terms of costs, life expectancy, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. To perform the analysis, we used DecisionMaker software beta version 2003.3.3.2 (S. G. Pauker, F. A. Sonnenberg, J. B. Wong, C. G. Hagerty, New England Medical Center, Boston, Mass). We performed 1-way, 2-way, multiway, and probabilistic sensitivity analyses by varying values for model parameters within specified ranges.

Table 1. Estimates for Clinical Probabilities in the Decision Model

<table>
<thead>
<tr>
<th>Variables: Clinical Effectiveness</th>
<th>Heparin Sodium Alone, %</th>
<th>Relative Risk for Alteplase Plus Heparin Sodium (Range)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality from PE</td>
<td>2.7</td>
<td>1.0 (0.36-6.80)</td>
<td>Konstantinides et al\textsuperscript{14}</td>
</tr>
<tr>
<td>Patients requiring treatment escalation</td>
<td>23.0</td>
<td>0.4 (0.16-0.66)</td>
<td>Konstantinides et al\textsuperscript{14}</td>
</tr>
<tr>
<td>ICH</td>
<td>0.4</td>
<td>3.0 (1.7-5.5)</td>
<td>Konstantinides et al\textsuperscript{13}</td>
</tr>
<tr>
<td>Severe bleeding</td>
<td>1.3</td>
<td>4.2 (2.8-4.8)</td>
<td>GUSTO Investigators,\textsuperscript{17} Simonneau et al\textsuperscript{18}</td>
</tr>
<tr>
<td>Minor bleeding</td>
<td>4.1</td>
<td>2.3 (1.0-4.9)</td>
<td>Sors et al\textsuperscript{16} Simonneau et al\textsuperscript{18}</td>
</tr>
</tbody>
</table>

Abbreviations: ICH, intracranial hemorrhage; PE, pulmonary embolism.

*Alteplase vs heparin sodium alone.
RESULTS

Based on data from the randomized, controlled trial performed by Konstantinides et al., we assumed that patients who received heparin alone required treatment escalation (rescue thrombolysis, mechanical ventilation, catecholamine infusion, or embolectomy) approximately 3 times more often than patients who received heparin plus alteplase (23.2% vs 7.6%) but that there was no difference in the risk of death from pulmonary embolism between the

Table 2. Estimates for Clinical Probabilities, Costs, and Quality of Life Adjustments (Utilities) in the Decision Model

<table>
<thead>
<tr>
<th>Variable</th>
<th>Both Heparin Sodium Alone and Alteplase</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients who received specific interventions, %*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Catecholamine infusion for persistent hypotension</td>
<td>24.0 (19.0-30.0)</td>
<td>Konstantinides et al.</td>
</tr>
<tr>
<td>Endotracheal intubation</td>
<td>13.0 (9.7-17.7)</td>
<td>Konstantinides et al.</td>
</tr>
<tr>
<td>Embolectomy</td>
<td>2.2 (0.1-4.8)</td>
<td>Konstantinides et al.</td>
</tr>
<tr>
<td>Rescue thrombolysis</td>
<td>100</td>
<td>Konstantinides et al.</td>
</tr>
<tr>
<td>Other clinical probabilities, %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early recurrent pulmonary embolism, first week</td>
<td>4.0 (2.5-6.4)</td>
<td>Carson et al.</td>
</tr>
<tr>
<td>Late recurrent pulmonary embolism, annual risk after first week</td>
<td>4.3 (2.7-6.8)</td>
<td>Carson et al., Arcasoy and Kreit</td>
</tr>
<tr>
<td>Death following recurrent PE</td>
<td>34 (30-44)</td>
<td>Goldhaber et al.</td>
</tr>
<tr>
<td>Death following ICH</td>
<td>45 (21-72)</td>
<td>Arcasoy and Kreit</td>
</tr>
<tr>
<td>Death following severe bleeding</td>
<td>4.9 (2.7-6.9)</td>
<td>Goldhaber et al.</td>
</tr>
<tr>
<td>Neurological deficits in survivors of ICH</td>
<td>62 (53-71)</td>
<td>Gore et al.</td>
</tr>
<tr>
<td>Patients requiring long-term nursing care following ICH</td>
<td>12 (9-15)</td>
<td>Mark et al.</td>
</tr>
<tr>
<td>Cost variables, $</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial hospitalization including treatment with heparin alone</td>
<td>6781 (5086-8476)</td>
<td>American Medical Association, Medical Economics, Centers for Medicare and Medical Services</td>
</tr>
<tr>
<td>Initial hospitalization including treatment with alteplase</td>
<td>9531 (7148-11 914)</td>
<td>American Medical Association, Medical Economics, Centers for Medicare and Medical Services</td>
</tr>
<tr>
<td>Costs common to both treatment groups</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrent late PE</td>
<td>8156 (6117-18 195)</td>
<td>American Medical Association, Medical Economics, Centers for Medicare and Medical Services</td>
</tr>
<tr>
<td>Cost of treatment escalation</td>
<td>14 515 (10 886-18 144)</td>
<td>Konstantinides et al., American Medical Association, Medical Economics, Centers for Medicare and Medical Services</td>
</tr>
<tr>
<td>Minor bleeding</td>
<td>898 (673-1122)</td>
<td>Solucient, American Medical Association</td>
</tr>
<tr>
<td>Nursing home care for disability after ICH, annual</td>
<td>51 000 (38 250-63 750)</td>
<td>Mahaffey et al.</td>
</tr>
<tr>
<td>Cost of complications for patients responding to primary treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICH</td>
<td>6930 (5198-8663)</td>
<td>Gore et al., American Medical Association, Medical Economics, Centers for Medicare and Medical Services</td>
</tr>
<tr>
<td>Recurrent early PE</td>
<td>5601 (4201-7001)</td>
<td>American Medical Association, Medical Economics, Centers for Medicare and Medical Services</td>
</tr>
<tr>
<td>Severe bleeding</td>
<td>2089 (1567-2611)</td>
<td>American Medical Association, Medical Economics, Solucient</td>
</tr>
<tr>
<td>Cost of complications for patients requiring treatment escalation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICH</td>
<td>4990 (3667-6111)</td>
<td>Gore et al., American Medical Association, Solucient, Mahaffey et al., Centers for Medicare and Medical Services</td>
</tr>
<tr>
<td>Recurrent early PE</td>
<td>4347 (3260-5433)</td>
<td>American Medical Association, Solucient, GUSTO III Investigators, Centers for Medicare and Medical Services</td>
</tr>
<tr>
<td>Severe bleeding</td>
<td>1370 (1027-1711)</td>
<td>American Medical Association, Solucient</td>
</tr>
<tr>
<td>Quality of life adjustments/utilities (duration of health state)†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PE (7 d)</td>
<td>0.60 (0.20-0.80)</td>
<td>Bell et al., Sarasin and Eckman</td>
</tr>
<tr>
<td>ICH (9 d)</td>
<td>0.12 (0.00-0.91)</td>
<td>Gage et al.</td>
</tr>
<tr>
<td>Severe bleeding (2 d)</td>
<td>0.76 (0.50-0.99)</td>
<td>Gage et al., Fryback et al.</td>
</tr>
<tr>
<td>Neurological disability following ICH (lifetime)</td>
<td>0.34 (0.00-1.00)</td>
<td>Gore et al., Mark et al., Fryback et al., Lee et al.</td>
</tr>
</tbody>
</table>

Abbreviations: ICH, Intracranial hemorrhage; PE, pulmonary embolism.
*Among those requiring treatment escalation.
†To calculate the decrement in quality-adjusted life expectancy associated with temporary health states, multiply the utility value by the duration of the health state. For example, the decrement in quality-adjusted life expectancy associated with recurrent pulmonary embolism is 0.6 × 7 days, or 4.2 quality-adjusted days.
2 groups (pooled risk, 2.7%). Based on data from a multicenter registry of 719 patients with acute pulmonary embolism, we estimated that the risk of intracranial hemorrhage (ICH) was 1.2% for patients treated with alteplase plus heparin and 0.4% for patients treated with heparin alone. Based on data from other sources, we assumed that the risk of other major bleeding complications was 4.2 times higher in patients who received thrombolytic therapy. In general, the effectiveness and cost-effectiveness of alteplase plus heparin became more favorable as the baseline risk of death decreased. For example, when the relative risk of death was less than or equal to 0.74 (base-case value = 1.0), thrombolysis was more effective and cost less than $50 000 per QALY gained when the relative risk of death was less than or equal to 0.68. Treatment with heparin alone remained more effective and less expensive when all other variables were tested across their specified ranges. Specifically, the cost-effectiveness of alteplase was not sensitive to the relative risk of treatment escalation or bleeding complications, the cost of alteplase, or the baseline risk of bleeding complications.

**Figure 2** shows the results of a 2-way sensitivity analysis that examined the baseline risk of death from pulmonary embolism in patients treated with heparin alone and the relative risk of death from pulmonary embolism associated with thrombolytic treatment. In general, the effectiveness and cost-effectiveness of alteplase plus heparin became more favorable as the baseline risk of death from pulmonary embolism increased and the relative risk of death decreased. For example, when the risk of death in the heparin cohort was 3 times the base-case value (8.1%), as has been reported in several observational studies of patients with submassive pulmonary embolism, thrombolytic therapy cost less than $50 000 per QALY gained, provided that the relative risk of death following treatment with alteplase was less than 0.90.

The results of a multiway sensitivity analysis that examined death from pulmonary embolism, intracranial hemorrhage, and treatment escalation showed that even when the relative risks of intracranial hemorrhage (1.7) and treatment escalation (0.16) were set at their lower limits, alteplase plus heparin cost less than $50 000 per QALY gained only when the relative risk of death was less than or equal to 0.86.

The results of a probabilistic sensitivity analysis favored heparin alone over alteplase plus heparin in more than 66% of 1000 simulations (Table 2). Heparin alone was more effective and less costly in 23% of all simulations, and it was more effective and cost less than $50 000 per QALY in another 44% of simulations. Alteplase plus

### Table 3. Health and Economic Outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Heparin Sodium Alone</th>
<th>Alteplase Plus Heparin Sodium</th>
<th>Difference*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present value of cost per patient, $†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial treatment</td>
<td>6689</td>
<td>9402</td>
<td>2713</td>
</tr>
<tr>
<td>Treatment escalation</td>
<td>3222</td>
<td>1102</td>
<td>-2220</td>
</tr>
<tr>
<td>Complications</td>
<td>1133</td>
<td>1446</td>
<td>313</td>
</tr>
<tr>
<td>Future health care</td>
<td>32 137</td>
<td>31 986</td>
<td>-151</td>
</tr>
<tr>
<td>Total Health Care Cost</td>
<td>43 281</td>
<td>43 936</td>
<td>655</td>
</tr>
</tbody>
</table>

Abbreviation: QALY, quality-adjusted life-year.
*Alteplase plus heparin minus heparin alone.
†Discounted at 3% annually.

### Base-Case Results

Discounted life expectancy and QALYs were greater in patients treated with heparin alone (10.57 years and 8.04 QALYs, respectively) than they were in patients who received alteplase plus heparin (10.52 years and 7.99 QALYs, respectively). The incremental difference in life expectancy was approximately 19 days (0.05 life-years). Discounted total lifetime costs were approximately $43 300 for patients who received heparin alone and $43 936 for patients treated with alteplase plus heparin. The incremental difference in costs was approximately $650. Patients who received treatment with alteplase plus heparin had higher costs for initial treatment ($9400 vs $6700) and treatment complications ($1450 vs $1100), but these were partly offset by lower costs for treatment escalation ($1100 vs $3300). Thus, under base-case assumptions, treatment with heparin alone was less expensive and more effective than treatment with alteplase plus heparin (**Table 3**).

### Sensitivity Analysis

In 1-way sensitivity analysis, the cost-effectiveness of alteplase plus heparin depended critically on the relative risk of death from pulmonary embolism following thrombolytic therapy. Under other base-case assumptions, treatment with alteplase plus heparin became more effective than heparin alone when the relative risk of death was less than or equal to 0.74 (base-case value = 1.0). Thrombolysis was more effective and cost less than $50 000 per QALY gained when the relative risk of death was less than or equal to 0.68. Treatment with heparin alone remained more effective and less expensive when all other variables were tested across their specified ranges. Specifically, the cost-effectiveness of alteplase was not sensitive to the relative risk of treatment escalation or bleeding complications, the cost of alteplase, or the baseline risk of bleeding complications.
heparin was more effective and more costly in 34% of all simulations. Alteplase plus heparin was never more effective and less expensive than heparin alone; however, it was more effective and cost less than $50 000 per QALY gained in 32% of simulations. As shown in Figure 3, cost-effectiveness acceptability curves showed that at a societal willingness-to-pay threshold of $50 000 per QALY gained, there was a 66% probability that heparin alone was cost-effective but only a 33% probability that thrombolysis was cost-effective.36

Under the assumptions of this analysis, we found that treatment with heparin alone was more effective and less costly than thrombolytic treatment with alteplase plus heparin in patients with submassive pulmonary embolism and right ventricular dysfunction. We demonstrated that the major determinants of effectiveness and cost-effectiveness were the baseline risk of death from pulmonary embolism following heparin treatment and the potential reduction in the risk of death given treatment with alteplase plus heparin. In contrast, the probability of clinical deterioration requiring treatment escalation did not have an impact on cost-effectiveness across the ranges tested in sensitivity analysis. Likewise, varying the risk of intracranial hemorrhage alone did not change the results. Thus, we showed that alteplase plus heparin must reduce the risk of death from pulmonary embolism to be cost-effective, even under optimistic assumptions about the risks of intracranial hemorrhage and clinical deterioration requiring treatment escalation.

The largest and most recent randomized controlled trial of thrombolysis in hemodynamically stable patients with pulmonary embolism and right ventricular dysfunction showed that treatment with alteplase plus heparin reduced the frequency of clinical deterioration requiring treatment escalation but not mortality rates.14 Although this study is the largest randomized trial performed to date (to our knowledge), it has several limitations that are relevant to this analysis. First, the patient population was defined as those with right ventricular dysfunction, yet only 30% of patients satisfied this definition based on echocardiographic criteria. Most met criteria for right ventricular dysfunction based on electrocardiographic findings alone. Second, the low combined mortality rate (2.7%) observed in this study suggests that the participants may have been less severely ill than patients with submassive pulmonary embolism and echocardiographic evidence of right ventricular dysfunction who were described in recent observational studies.9,13 Third,
the study protocol permitted investigators to break the
treatment code for patients who were clinically deterio-
rating. Thus, in some cases, the decision to escalate treat-
ment may have been influenced by knowledge of whether
the patient was assigned to receive primary thromboly-
sis. Although treatment with alteplase plus heparin
was not associated with lower mortality rates in the ran-
donized controlled trial, primary thrombolysis was asso-
ciated with a reduced requirement for treatment escala-
tion, prompting the study authors to recommend primary therapy with alteplase. However, our results sug-
gest that available data do not support the routine use of
primary thrombolysis in this patient population.

Sensitivity analysis showed that the relative risk of
death from pulmonary embolism had the greatest poten-
tial impact on the cost-effectiveness of thrombolytic therapy. Not surprisingly, a 2-way sensitivity analysis
showed that treatment with alteplase plus heparin be-
came a more attractive option as the baseline risk of death following treatment with heparin alone increased, pro-
vided that there was at least some reduction in the risk of
death owing to treatment with alteplase plus heparin.
This analysis underscores the potential importance of fur-
ther risk stratification in hemodynamically stable pa-
tients with pulmonary embolism. Recent studies of
patients with elevated serum levels of B-type natriuretic
peptide and cardiac troponins show promise in identi-
fying a subgroup of hemodynamically stable patients for
whom the risk of death is markedly elevated. More re-
cently, Aujesky et al developed and validated a clini-
cal model that identified patients with an increased risk
of death from acute pulmonary embolism. In future stud-
ies, use of this model and other prognostic biomarkers
should help identify subgroups of patients who might ben-
efit most from treatment with alteplase plus heparin.

Our analysis has several limitations. First, we did not
consider several potential mechanisms by which alteplase
may improve outcomes over heparin alone. These mecha-
nisms include reducing the rate of recurrent thrombo-
elysis and the potential reduction in long-term complica-
tions of venous thromboembolism such as pulmonary
hypertension and the postthrombotic syndrome. These
potential benefits have not been conclusively demon-
strated in clinical studies. If confirmed, primary throm-
bolysis would be a more attractive option. Second, we did
not consider the use of vena cava filters in patients who
developed severe bleeding. The need for vena cava filters
would be higher in the group that received thrombolysis
treatment, and not including this outcome would lead to
bias in favor of thrombolysis. This does not threaten the
validity of our conclusions because including vena caval
filters would make the thrombolysis arm slightly less cost-
effective than it already is in comparison with treatment
with heparin alone. Last, although we assumed that alte-
plase plus heparin did not reduce the risk of death from
pulmonary embolism (based on the best available data),
observational studies suggest that primary thrombolysis may
improve mortality rates in some populations of patients with
submassive pulmonary embolism and right ventricular dys-
function. For example, in the Management Strategies and
Determinants of Outcome in Acute Major Pulmonary Em-
bolism registry, the population of patients with right ven-
tricular dysfunction had a higher baseline mortality rate
(8.1%) and satisfied a stricter definition of right ventricular
dysfunction (echocardiographic or angiographic criteria
rather than electrocardiographic criteria alone) com-
pared with those patients included in the randomized
controlled trial by Konstantinides et al. In this registry,
the unadjusted relative risk of death from PE following
thrombolysis was 0.62. In addition, smaller randomized
trials have consistently shown that treatment with throm-
bolysis improves right ventricular dysfunction more than
treatment with heparin alone. However, it is not clear
whether improvement in physiologic outcomes can be trans-
lated to improved survival.

It may be very difficult to perform a randomized, con-
trolled trial that is adequately powered to demonstrate that alteplase plus heparin improves survival. We esti-
mate that such a trial would have to enroll at least 2800
participants in each arm to detect a 30% reduction in the
risk of pulmonary embolism–related death with 80% power at an α level of .05, assuming that the baseline risk
of death in the control group was 5%. The required sample
size would need to be even larger to detect smaller re-
ductions in risk. The promise of greater safety and effi-
cacy with catheter-directed thrombolysis also requires
confirmation in large clinical trials.

In summary, by synthesizing the best available evi-
dence on effectiveness, complications, and costs, we found
that treatment with alteplase plus heparin is less effec-
tive and more costly than treatment with heparin alone.
Current evidence does not support the routine use of pri-
mary thrombolysis in hemodynamically stable patients
with acute pulmonary embolism and right ventricular dys-
function, as defined by electrocardiographic criteria,
echocardiographic criteria, or right heart catheterization.
Future studies should explore whether thrombo-
lolytic therapy is more effective in other subgroups of
hemodynamically stable patients who are at greater risk
of death from acute pulmonary embolism.

Accepted for Publication: September 21, 2006.
Correspondence: Michael K. Gould, MD, MS, Veterans
Affairs Palo Alto Health Care System (111P), 3801
Miranda Ave, Palo Alto, CA 94304 (gould@stanford.
edu).
Author Contributions: Dr Gould had full access to all of
the data in the study and takes responsibility for the
integrity of the data and the accuracy of the data analy-
sis. Study concept and design: Perlroth, Sanders, and Gould.
Acquisition of data: Perlroth, Sanders, and Gould. Analysis and
interpretation of data: Perlroth, Sanders, and Gould. Draft-
ing of the manuscript: Perlroth and Gould. Critical revi-
sion of the manuscript for important intellectual content:
Study supervision: Sanders and Gould.
Financial Disclosure: None reported.
Funding/Support: At the time this study was per-
formed, Dr Gould was supported by an Advanced Research
Career Development Award from the Department of Veterans Affairs Health Services Research
and Development Service (RCD 99-023-2).

Acknowledgment: We thank Ellen Thompson, MS, for
assistance with manuscript preparation.
REFERENCES


